Abstract
Resistance to antiepileptic drugs (AED) remains a major problem in clinical epileptology. This pharmacoresistance is independent of the choice of AEDs. Different hypotheses have been proposed to explain the neurobiological basis for pharmacoresistance in epilepsy. The transporter hypothesis is the mostly investigated theory. Hereby, overexpression of multidrug efflux transporters, such as P-glycoprotein (Pgp), at the blood-brain-barrier (BBB) is thought to be involved in pharmacoresistance in epilepsy by extruding AEDs from their target site. Accumulating evidence supports an overexpression of Pgp in pharmacoresistant epilepsy. Molecular Imaging studies provide unique opportunities for the in-vivo study of the transporter hypothesis in the central nervous system (CNS). Several studies demonstrated that positron emission tomography (PET) with [11C]-radiolabled Pgp substrates is a promising tool for in vivo investigation of Pgp function at the rat, monkey and human BBB. Quantification of Pgp over activity in epilepsy patients by in vivo imaging could be highly useful because altered treatment strategies or novel AED could then be applied.
Keywords: Blood-brain-barrier, P-glycoprotein, positron emission tomography, drug transporter, epilepsy.
Current Pharmaceutical Design
Title:ABC Transporters and Drug Resistance in Patients with Epilepsy
Volume: 22 Issue: 38
Author(s): Maria Feldmann and Matthias Koepp
Affiliation:
Keywords: Blood-brain-barrier, P-glycoprotein, positron emission tomography, drug transporter, epilepsy.
Abstract: Resistance to antiepileptic drugs (AED) remains a major problem in clinical epileptology. This pharmacoresistance is independent of the choice of AEDs. Different hypotheses have been proposed to explain the neurobiological basis for pharmacoresistance in epilepsy. The transporter hypothesis is the mostly investigated theory. Hereby, overexpression of multidrug efflux transporters, such as P-glycoprotein (Pgp), at the blood-brain-barrier (BBB) is thought to be involved in pharmacoresistance in epilepsy by extruding AEDs from their target site. Accumulating evidence supports an overexpression of Pgp in pharmacoresistant epilepsy. Molecular Imaging studies provide unique opportunities for the in-vivo study of the transporter hypothesis in the central nervous system (CNS). Several studies demonstrated that positron emission tomography (PET) with [11C]-radiolabled Pgp substrates is a promising tool for in vivo investigation of Pgp function at the rat, monkey and human BBB. Quantification of Pgp over activity in epilepsy patients by in vivo imaging could be highly useful because altered treatment strategies or novel AED could then be applied.
Export Options
About this article
Cite this article as:
Feldmann Maria and Koepp Matthias, ABC Transporters and Drug Resistance in Patients with Epilepsy, Current Pharmaceutical Design 2016; 22 (38) . https://dx.doi.org/10.2174/1381612822666160810150416
DOI https://dx.doi.org/10.2174/1381612822666160810150416 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transitional Polytherapy: Tricks of the Trade for Monotherapy to Monotherapy AED Conversions
Current Neuropharmacology The Effect of Mianserin on Lifespan of <i>Caenorhabditis elegan</i> is Abolished by Glucose
Current Aging Science Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization
Current Pharmaceutical Design Mygalin: A New Anticonvulsant Polyamine in Acute Seizure Model and Neuroethological Schedule
Central Nervous System Agents in Medicinal Chemistry Neuropharmacological Aspects of Crocus sativus L.: A Review of Preclinical Studies and Ongoing Clinical Research
CNS & Neurological Disorders - Drug Targets Benzimidazole Derivatives as Centerally Acting Agents
Current Drug Therapy Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry ERRATUM 2
Current Neuropharmacology Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Effects of Low Doses of Polyunsaturated Fatty Acids on the Attention Deficit/Hyperactivity Disorder of Children: A Systematic Review
Current Neuropharmacology Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders
Current Molecular Medicine Glycyrrhizic Acid Ameliorates Cognitive Impairment in a Rat Model of Vascular Dementia Associated with Oxidative Damage and Inhibition of Voltage-Gated Sodium Channels
CNS & Neurological Disorders - Drug Targets Editorial (Adverse Effects, Adverse Events and Side-Effects: Does the Terminology Matter?
Current Drug Safety Treatment of Estrogen Receptor-Positive Breast Cancer
Current Medicinal Chemistry Current Understanding of Central Nervous System Drainage Systems: Implications in the Context of Neurodegenerative Diseases
Current Neuropharmacology Importance of P-gp PET Imaging in Pharmacology
Current Pharmaceutical Design Cerebroprotective Functions of HO-2
Current Pharmaceutical Design Evolving Mechanistic Concepts of Epileptiform Synchronization and their Relevance in Curing Focal Epileptic Disorders
Current Neuropharmacology MicroRNAs as Biomarkers for Birth Defects
MicroRNA Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Current Pharmaceutical Design